Clinical Trials
6 trialsNCT01838395 2024-09-19
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
BioLineRx, Ltd.
Phase 2 Completed
NCT03154827 2024-09-05
Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)
BioLineRx, Ltd.
Phase 1/2 Terminated
NCT02639559 2023-11-07
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
Phase 2 Completed
NCT02763384 2023-10-31
BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Washington University School of Medicine
Phase 2 Terminated
NCT02115672 2016-08-15
Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia
Sheba Medical Center
Phase 1/2 Withdrawn
NCT02502968 2015-09-21
BLAST
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Unknown